Evidence map›Paper›PMID 30228265›Full record

Trial reportClinical and translational gastroenterology2018

Combination of Gluten-Digesting Enzymes Improved Symptoms of Non-Celiac Gluten Sensitivity: A Randomized Single-blind, Placebo-controlled Crossover Study.

Hiroki Ido, Hirotaka Matsubara, Manabu Kuroda, Akiko Takahashi, Yuzo Kojima, Satoshi Koikeda, Makoto Sasaki

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and translational gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05744700 (A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Tolerability of Microbial Inulinase), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05744700 nacompletednot on this mapstarted 2023, after this paper: background citation

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Tolerability of Microbial Inulinase

TypeinterventionalSponsorBIO-CAT, Inc.Ran2023 to 2023Enrolled60ConditionsDigestive Health, Gastrointestinal HealthArmsInulinase, Maltodextrin placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Heliyon · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Protein Digestibility of Cereal Products.Foods (Basel, Switzerland) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hiroki IdoAmano Enzyme Inc., Nagoya, Japan.
Hirotaka MatsubaraAmano Enzyme Inc., Nagoya, Japan.
Manabu KurodaAmano Enzyme Inc., Nagoya, Japan.
Akiko TakahashiAmano Enzyme Inc., Nagoya, Japan.
Yuzo KojimaAmano Enzyme Inc., Nagoya, Japan.
Satoshi KoikedaAmano Enzyme Inc., Nagoya, Japan. satoshi_koikeda@amano-enzyme.com.
Makoto SasakiDepartment of Gastroenterology, Aichi Medical University School of Medicine, Nagakute, Japan.
Amano Enzyme (Japan) · JPAichi Medical University · JPSatou Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecently, the population of individuals with non-celiac gluten sensitivity (NCGS) who do not have celiac disease but show improved symptoms with a gluten-free diet, has increased. Enzyme replacement therapy using digestive enzymes is expected to improve the symptoms of NCGS and be sustainable, since gluten-related proteins that are indigestible by the digestive system have been considered triggers of NCGS.

methodsWe selected patients with NCGS by screening demographic interviews, as well as performing medical evaluations, anti-gluten antibody tests, and gluten challenge tests. We performed a single-blind and crossover clinical trial with these subjects using a gluten challenge with the enzyme mixture or a placebo. Our designed enzyme mixture contained peptidase, semi alkaline protease, deuterolysin, and cysteine protease derived from Aspergillus oryzae, Aspergillus melleus, Penicillium citrinum, and Carica papaya L., respectively.

resultsAdministration of the enzyme mixture significantly decreased the change in the score of the symptom questionnaire before and after the gluten challenge compared with administration of the placebo in patients with NCGS without adverse events. In particular, the changes in the score of the gluten-induced incomplete evacuation feeling and headaches were significantly improved. The serum levels of interleukin (IL)-8, tumor necrosis factor (TNF)-α, andregulated on activation, normal T cell expressed and secreted (RANTES) in subjects were not significantly changed by gluten, as expected from previous studies, and the enzyme mixture did not affect these inflammatory markers.

conclusionIn this human clinical study, we demonstrated the efficacy of the enzyme mixture derived from microorganisms and papaya in improving the symptoms of NCGS.

Indexed as

Enzyme Replacement TherapyAdultAgedAspergillusBacterial ProteinsCaricaCross-Over StudiesCysteine ProteasesCytokinesDiet, Gluten-FreeDigestionEndopeptidasesFemaleFood HypersensitivityGlutensHumansalkaline proteaseBacterial ProteinsCysteine ProteasesCytokinesEndopeptidasesGlutensPeptide Hydrolases

Identifiers

PMID30228265
PMCPMC6143542
OpenAlexW2890164952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.